公开(公告)号：US08039486B2

公开(公告)日：2011-10-18

申请号：US12028189

申请日：2008-02-08

申请人： Kap-Sun Yeung ,  Michelle E. Farkas ,  John F. Kadow ,  Nicholas A. Meanwell ,  Malcolm Taylor ,  David Johnston ,  Thomas Stephen Coulter ,  J. J. Kim Wright

发明人： Kap-Sun Yeung ,  Michelle E. Farkas ,  John F. Kadow ,  Nicholas A. Meanwell ,  Malcolm Taylor ,  David Johnston ,  Thomas Stephen Coulter ,  J. J. Kim Wright

IPC分类号： A61K31/04 ,  C07D215/38

CPC分类号： C07D413/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D491/04

摘要： This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is

摘要翻译： 本发明提供具有药物和生物影响性质的式I化合物，包括其药学上可接受的盐，其药物组合物和使用方法。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。 式I的化合物具有下式：其中：Z为Q选自m为2; A选自噌啉基，萘啶基，喹喔啉基，吡啶基，嘧啶基，喹啉基，异喹啉基，喹唑啉基，氮杂苯并呋喃基和酞嗪基，其各自可以任选被一个或两个独立地选自甲基，甲氧基，羟基，氨基 和卤素; 和-W-是

公开(公告)号：US20080132516A1

公开(公告)日：2008-06-05

申请号：US12028189

申请日：2008-02-08

申请人： Kap-Sun Yeung ,  Michelle E. Farkas ,  John F. Kadow ,  Nicholas A. Meanwell ,  Malcolm Taylor ,  David Johnston ,  Thomas Stephen Coulter ,  J.J Kim Wright

发明人： Kap-Sun Yeung ,  Michelle E. Farkas ,  John F. Kadow ,  Nicholas A. Meanwell ,  Malcolm Taylor ,  David Johnston ,  Thomas Stephen Coulter ,  J.J Kim Wright

IPC分类号： A61K31/496 ,  C07D401/14 ,  A61P31/18

CPC分类号： C07D413/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D491/04

摘要： This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is

摘要翻译： 本发明提供具有药物和生物影响性质的式I化合物，包括其药学上可接受的盐，其药物组合物和使用方法。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。 式I的化合物具有下式：其中：Z为Q选自m为2; A选自噌啉基，萘啶基，喹喔啉基，吡啶基，嘧啶基，喹啉基，异喹啉基，喹唑啉基，氮杂苯并呋喃基和酞嗪基，其各自可以任选被一个或两个独立地选自甲基，甲氧基，羟基，氨基 和卤素; 和-W-是

公开(公告)号：US09630950B2

公开(公告)日：2017-04-25

申请号：US14027073

申请日：2013-09-13

申请人： Peter B. Dervan ,  Nicholas G. Nickols ,  Claire S. Jacobs ,  Michelle E. Farkas ,  Daniel A. Harki

发明人： Peter B. Dervan ,  Nicholas G. Nickols ,  Claire S. Jacobs ,  Michelle E. Farkas ,  Daniel A. Harki

IPC分类号： C07D403/14 ,  A61K31/785

CPC分类号： C07D403/14 ,  A61K31/4178 ,  A61K31/785

摘要： The present invention relates to polyamides capable of inhibiting ARE-, GRE- and ERE-mediated gene regulation in cells. The present invention also relates to polyamides capable of modulating the activity of RNA polymerase II and p53. The invention also relates to methods to treat diseases related to ARE-, GRE- and ERE-mediated gene regulation and to RNA polymerase II and p53 activity.